More Stories

Informist, Tuesday, Jul. 21, 2026

 

Please click here to read all liners published on this story

--Anthem Biosciences Apr-Jun consol PAT INR 1.20 bln 
--Anthem Biosciences Apr-Jun consol revenue INR 4.18 bln 
--Anthem Biosciences Apr-Jun consol PAT INR 1.20 bln vs INR 1.36 bln year ago 
--Anthem Biosciences Apr-Jun consol revenue INR 4.18 bln vs INR 5.40 bln year ago 
--Anthem Biosciences Q1 contract mfg ops sales INR 34.1 bln vs INR 45.3 bln 
--Anthem Biosciences Q1 consol EBITDA INR 1.76 bln vs INR 2.14 bln yr ago 
--[Anthem Biosciences Apr-Jun consol EBITDA margin 39.6% vs 38.1% yr ago 
--Anthem Biosciences MD:Q1 reflects timing shifts in delivery to key clients 
--Anthem Biosciences MD: Higher deliveries scheduled for latter half of FY27

 

By Gopika Balasubramanium

 

MUMBAI – Anthem Biosciences Ltd.'s net profit for the June quarter plunged on year due to a sharp fall in sales, even as the expenses saw a substantial fall. The fall in sales was likely due to shifts in timings of deliveries to key clients. 

 

"Our Q1FY27 quarterly results reflect timing shifts in deliveries to key customers," Ajay Bhardwaj, the company's managing director and chief executive officer said. "The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum," he added.

 

While the pharmaceutical company's bottom line fell 12% on year to INR 1.20 billion, its revenue from operations saw a sharper 23?ll to INR 4.18 billion. Sequentially, the net profit fell around 37% and sales fell around 32%. 

 

The company's revenue from contract research, development, and manufacturing operations fell around 25% on year to INR 3.41 billion for the quarter under review. The company earned INR 774 million from sales of speciality ingredients, which fell 11.5% on year.  

 

The company's earnings before interest, tax, depreciation, and amortisation fell 18% on year to INR 1.76 billion. Its EBITDA margin expanded to 39.6% from 38.1% reported in the year-ago quarter. 

 

 

In Apr-Jun, the company's total expenditure, including finance cost, fell around 21% on year to about INR 3 billion. The company spent INR 1.49 billion to buy raw materials for its operarions and this cost fell over 8% on year. Its employee benefit expenses rose over 9% on year to INR 788.36 million.

 

The company's tax outgo for the June quarter fell to INR 246.40 million as against INR 504.58 million a year ago. Its depreciation and amortisation expenses rose a little over 13% on year to INR 300 billion. 

 

The company reported its earnings post market hours on Tuesday. Its shares closed flat at INR 791.55 on the National Stock Exchange.  End 

 

Edited by Akul Nishant Akhoury

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.